Member Info for Energyshares

We should see a big rise on Wednesday when all these imaginary shares are not allocated and all these greedy bast .ards
who were expecting to buy massive chunks of shares at 95p have to buy in at SP.

Here is the start of her speech…

Revolutionising the treatability of solid tumours.

https://m.youtube.com/watch?v=sahPC4l1Y3c

Can all who want to discuss their shareholding please go back to the Telegram group.

FFS

Pathfinder:
one that discovers a way especially : one that explores untraversed regions to mark out a new route.

Another word for pathfinder

Pioneering:

Straight out of the Wetherby dictionary :):)

GLA

Wonder what the neighbours think?
;););)

https://twitter.com/rah00084/status/1588298939018739712?s=46&t=Uc7fBgvB7gKkwwDEG2Mi6Q

Secret footage of the compare practising for Fiona’s presentation on Saturday.

https://m.youtube.com/watch?v=2hMkcb96tnY

“A Jersey cash box structure”
Big Al loves a good jumper.

https://www.careyolsen.com/news-and-deals/carey-olsen-advises-avacta-group-£55-million-bond-issuance

Think of the patients.

Results will come when 1a completes.

Launch Diagnostics now added this paragraph below to each item they sell on their website.

Nice to see we now have guaranteed income coming in and a easy route to market for any new diagnostics tests produced in house.

Launch Diagnostics is a licensed reseller and distributor of Accusay Calprep
Launch Diagnostics, part of the Avacta group, provides pathology solutions encompassing high quality diagnostic reagents and instrumentation from world leading manufacturer’s to the Health Services of the United Kingdom, Belgium, Luxemburg, France through Launch Diagnostics SAS and to the Republic of Ireland through ACCUSAY Diagnostics.
Offering a large portfolio of diagnostic kits, laboratory instrumentation and services, our product range has expanded over the years to include a comprehensive range of EIA, single test devices, serology products, molecular assays and instrumentation.

https://www.launchdiagnostics.com/product/accusay-calprep/

Cohort 4 could complete tomorrow.
Do they finish and crack on with 1b or move to Cohort 5 and try and find MTD.

I wouldn’t mind if they went higher, but they would have to RNS that it works including biopsies to satisfy the market.

GLA

Han**** having his last holiday before a long prison sentence after covid enquiry.

AS has learnt a lot with trying to work with UK Gov.
Avacta won’t make those mistakes again.

Affimers v Antibodies

This company has so many shots on goal.

https://m.youtube.com/watch?v=V6YbTZEfpNo

Little bit of info on third bridge:

https://m.youtube.com/watch?v=GAQ1cdibARM

Takeda -neighbours
Novartis-neighbours
Sofie -Co sponsors
Merck -cash rich
J&J-cash rich
Pfizer-cash rich

Who makes a move first,once data announced.

Can Avacta Therapeutics stay independent ?

Great times to be a Avacta LTH.

Avacta LinkedIn statement:

Fiona will be delivering a key update on Avacta Therapeutics’ lead pre|CISION™ programme, AVA6000 – a tumour-activated form of doxorubicin – on Sat 5th Nov
Then in brackets:
(“Pre-clinical Development of AVA6000 – a FAP targeted chemotherapeutic agent in Phase I”,)

My take on this, why would you give a KEY UPDATE on pre-clinical data if the trial has been going for 27 months,and pre-clinical data has already been presented to AACR in April.

I think the KEY UPDATE has got to be trial data V’s pre-clinical data.

PAH00
Get your machines on eBay quick,ARB just sold 3,843 new-in-box Bitmain S19J Pro machines.

You should get a good price…

CSO description

The technology delivers a drug which is much better tolerated, enabling further treament cycles to be administered.

(It Works)

Official RNS description

AVA6000 is a form of the generic chemotherapy doxorubicin that has been modified using Avacta's pre|CISION technology so that it is activated by FAP, predominantly in the tumour, with the aim of sparing healthy tissue from exposure and improving the safety, tolerability and efficacy of the drug.

(We will tell you later It Works)

Do reckon Fiona is on time and a 1/2 or double time for working Saturday.

:):):)

Fiona will be delivering a KEY update on Avacta Therapeutics’ lead pre|CISION™ programme, AVA6000 – a tumour-activated form of doxorubicin – on Sat 5th Nov